Design Therapeutics Inc logo

DSGN

Design Therapeutics Inc

$22.13

Earnings Summary

Revenue
$0Mn
Net Profits
$-13.27Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Design Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Design Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Design Therapeutics Inc’s net profit fell -140.57% since last year same period to $-13.27Mn in the Q1 2022. On a quarterly growth basis, Design Therapeutics Inc has generated -19.88% fall in its net profits since last 3-months.

Net Profit Margins:

Design Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Design Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Design Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

Design Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a -13.64% fall from last quarter’s estimates.

EPS Estimate Current Year:

Design Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the Design Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.24
Return on Assets (ROA)
-0.08
Return on Equity (ROE)
-0.13
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Design Therapeutics Inc’s earning per share (EPS) jumped 22.58% since last year same period to -0.24 in the Q1 2022. This indicates that the Design Therapeutics Inc has generated 22.58% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Design Therapeutics Inc’s return on assets (ROA) stands at -0.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Design Therapeutics Inc’s return on equity (ROE) stands at -0.13.

Dividend Per Share (DPS):

Design Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.22
-0.24
-9.09%

Company Information

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

Organisation
Design Therapeutics Inc
Employees
15